Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO RESPICLICK versus ALVESCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO RESPICLICK versus ALVESCO.
AIRDUO RESPICLICK vs ALVESCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone propionate (corticosteroid) and salmeterol (long-acting beta2-adrenergic agonist); fluticasone reduces inflammation via glucocorticoid receptor activation, salmeterol relaxes bronchial smooth muscle via beta2-receptor stimulation.
Ciclesonide is a prodrug that is converted to the active metabolite des-ciclesonide, which has anti-inflammatory activity by binding to glucocorticoid receptors, thereby inhibiting inflammatory mediators such as cytokines and leukotrienes.
Two inhalations (55 mcg/113 mcg per inhalation) twice daily via oral inhalation; maximum 2 inhalations twice daily. For patients with asthma, starting dose is one inhalation twice daily; may increase to two inhalations twice daily after 1-2 weeks if inadequate response.
Inhalation: 160 mcg twice daily (morning and evening). May be increased to 320 mcg twice daily if inadequate response. Maximum 640 mcg twice daily.
None Documented
None Documented
Salmeterol: terminal elimination half-life of 5.5 hours. Fluticasone furoate: terminal elimination half-life of approximately 24 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 2-3 hours for the systemically absorbed fraction; however, the receptor occupancy half-life is significantly longer due to lipophilic tissue binding, providing therapeutic duration of 12 hours.
Renal elimination of salmeterol: approximately 25% of dose excreted unchanged in urine. Fluticasone furoate: primarily excreted as metabolites in feces (≥90%) following intravenous administration, with less than 5% excreted in urine.
Primarily hepatic metabolism (CYP3A4) to less active metabolites; renal excretion accounts for <10% unchanged; fecal excretion as metabolites ~80%.
Category C
Category C
Inhaled Corticosteroid/LABA Combination
Inhaled Corticosteroid